Join to View Full Profile
100 High StBuffalo, NY 14203
Phone+1 716-859-5600
Dr. Silvestri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Neurology, 2005 - 2009- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2004 - 2005
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2004- Beth Israel Deaconess Medical Center/Harvard Medical SchoolFellowship, Neuromuscular Medicine (Neurology)
Certifications & Licensure
NY State Medical License 2009 - 2026
MA State Medical License 2008 - 2011
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- International Guillain-Barré Syndrome Outcome Study Start of enrollment: 2012 May 01
Publications & Presentations
PubMed
- What Patients Don't Say and Physicians Don't Ask: A Needs Assessment in Myasthenia Gravis Integrating Patient and Healthcare Professional Perspectives.Cornelia Reyes Acosta, Ivo Vlaev, Alexis Rodriguez, Allison Foss, Ashwin Pinto
Neurology and Therapy. 2025-08-01 - 2 citationsLarge-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome.Robin C M Thomma, Susan K Halstead, Laura C de Koning, Evelin E J A Wiegers, Dawn S Gourlay
Brain. 2025-03-17 - 1 citationsA case report of elevated bromide levels from pyridostigmine bromide for treatment of myasthenia gravis.Aubrey Defayette, Elizabeth Anibaldi, Ajay Abad, Chinazom Ibegbu, Nicholas Silvestri
American Journal of Health-System Pharmacy. 2024-12-16
Press Mentions
FDA Nod for J&J Autoimmune Drug Is First of Potentially Many for the Projected Blockbuster ProductMay 1st, 2025- Johnson & Johnson Receives FDA Approval for IMAAVY™ (Nipocalimab-Aahu), a New FcRn Blocker Offering Long-Lasting Disease Control in the Broadest Population of People Living with Generalized Myasthenia Gravis (gMG)April 30th, 2025
- JnJ Imaavy Gets USFDA Okay for Generalized Myasthenia GravisApril 30th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
